Necon 1 / 50 is a high dose birth control drug. It is manufactured to conduct preventive measures to become pregnant.
Indications for use
Necon 1 / 50 is prescribed as a contraceptive means.
Mechanism of action
Necon 1 / 50 is a high dose monophasic combined oral contraceptive containing estrogen and progestin.
The complementary mechanisms are involved to provide a contraceptive effect of this birth control. The most significant mechanism is the suppression of ovulation. Necon takes part in changes in the cervical secretion properties. Finally, it becomes almost impossible for sperm to enter the uterine cavity.
Women who take combined birth control drugs, the menstrual cycle becomes more regular. The painful sensations disappear, the intensity of periods decreases, resulting in a reduced risk of iron deficiency anemia. In addition, there is a proved evidence that the risk of endometrial and ovarian cancer is reduced.
Mode of application and dosage
Eacg Necon 1/50 package usually contains 28 tablets. Take 1 tablet daily for 28 days ina row. There is no interruption in the pills’ application. The drug should be taken at one and the same time washed down with a full glass of water. The latest pills contain no hormone. When taking these placebo pills the menstruation will start.
The package may also contain 21 tablets. In this case, the package contains no hormone-free tablets. Take 1 tablet daily for 21 days in row. Then don’t take any tablets for 7 days. You’ll get your period during the hormone-free week while you aren’t taking any active tablets.
Necon 1 / 50 is contraindicated in the following health conditions:
- venous and arterial thrombosis and thromboembolism currently or in the medical history inclusively deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular disorders;
- currently diagnosed or previously transferred medical conditions preceding thrombosis inclusively of transient ischemic attacks, angina pectoris;
- currently diagnosed or previously transferred migraine accompanied by focal neurological symptoms;
- diabetes complicated by vascular disorders;
- multiple or severe risk factors for venous or arterial thrombosis;
- diagnosed or transferred pancreatitis complicated by severe hypertriglyceridemia;
- hepatic failure and hepatic disease of severe form;
- liver tumors (benign or malignant): currently diagnosed or previously transferred;
- identified hormone-dependent malignant diseases;
- vaginal bleeding of unknown origin;
- pregnancy or lactation;
- hypersensitivity to any of the components.
- Cardiovascular system: arterial hypertension, myocardial infarction, cerebral circulation disorder, deep vein thrombosis, arterial thromboembolism, pulmonary or other thromboembolism, edema.
- Tumors: benign and malignant hepatic tumors, cervical and breast cancer.
- Hepatobiliary system: cholestatic jaundice, venoocclusive disease of the liver (Budd-Chiari syndrome), intrahepatic cholestasis, cholelithiasis.
- Gastrointestinal: nausea, vomiting, abdominal pain, flatulence, colitis.
- Genital organs: intermenstrual bleeding, spotting, amenorrhea, changes in the menstrual cycle, increase in the size of uterine fibroids, vaginal candidiasis, increase in cervical secretion, erosion of the cervical cavity, decreased libido, premenstrual syndrome, temporary infertility after the end of the drug.
- Breast glands: a sensation of tension, galactorrhea, tenderness, increase in size, decrease in lactation when taken immediately after birth.
- Skin: erythema nodosum, skin rash, chloasma, erythema multiforme, acne, seborrhea, alopecia, hirsutism, pigment spots on the face, hypertrichosis, pemphigoid (gestational herpes), melasma.
- Organs of vision: cataract, lesion of the optic nerve, change in the corneal curvature, discomfort when wearing contact lenses.
- Central nervous system: headache, mood changes, irritability, depression, chorea.
- Metabolism: fluid body retention, changes in body weight (decrease or increase), decreased glucose tolerance, changes in appetite.
- Kidneys: reduced kidney function, hemolytic-uremic syndrome.
- Others: dizziness, migraine.
The interaction of oral contraceptives including Necon 1 / 50 with other drugs can result in breakthrough bleeding and/or a decrease in contraceptive effect.
Effect on hepatic metabolism: the application of drugs that induce hepatic microsomal enzymes can result in an increase in the sex hormones clearance. The following drugs are included in this list: phenytoin, primidone, barbiturates, carbamazepine, rifampicin; there are also suggestions for oxcarbazepine, topiramate, ritonavir and griseofulvin and remedies having St. John’s wort in composition.
Effects on the intestinal-hepatic circulation: according to individual scientific studies, some antibiotics (for example, penicillin and tetracycline) can decrease the intestinal hepatic circulation of estrogen.
When taking antibiotics (such as ampicillin and tetracycline) and for 7 days after their withdrawal, every woman should additionally apply a barrier method of contraception.
What if I miss a dose?
In case of missing the usual time of admission, the pill should be taken immediately. The delay from the usual application time less than 12 hours ensures a proper contraceptive effect. The effectiveness of the drug decreases when the pill is taken for more than 12 hours.
If more than 12 hours have passed from the usual time of taking the drug or if more than 1 tablet is skipped, then you should immediately resume taking the drug to avoid the premature menstrual bleeding. However, before the end of this cycle, you should use additional means of protection from pregnancy, such as a condom or vaginal contraceptive suppositories.
Necon 1/50 and pregnancy
Necon 1/50 is not prescribed during pregnancy and lactation. If pregnancy is established while taking this birth control, the drug should be immediately discontinued. However, extensive epidemiological studies have not revealed any increased risk of developmental defects in children whose mothers were applied birth control pills in the early stages of pregnancy.
Taking combined oral contraceptives can reduce the amount of breast milk and change its composition, therefore, as a rule, their use is not recommended during lactation.